After four years, those who took GLP-1 drugs had a 7% lower risk of developing an obesity-related cancer and an 8% lower risk ...

Newly recognized issues, including extreme fatigue with excessive weight reduction, bone loss, and abdominal pain, point to ...

After questions and criticism online, Janelle Rohner says she should have disclosed her decision to take a GLP-1.

If you're one of the millions of Americans who have used or thought about using GLP-1 weight-loss drugs, it’s important to ...

New review confirms psychiatric safety of commonly used glucagon-like peptide 1 receptor agonists among patients without ...

Xavier said that patients are often reluctant to quit smoking because they are fearful that they will gain weight. By adding ...

Novo Nordisk will sell a less expensive one-month supply of Wegovy for patients who previously took compounded versions of ...

Research on weight loss drugs like Ozempic shows varied results for mental health impacts, with some patients experiencing ...

Dr. Rubinstein has years of experience working with patients to help them achieve their desired goals in a realistic, ...

India's healthtech space is expected to witness disruption as weight loss drugs Ozempic and Mounjaro enter the market through ...

Researchers found GLP-1s may modestly reduce the risk of 14 obesity-related cancers, especially colorectal cancer, when compared to a weight-neutral medication used to treat diabetes.

The agreements cap monthly out-of-pocket costs for Zepbound and Wegovy at $200 and more deeply discount the drugs for ...